CPT code 0223U denotes a Proprietary Laboratory Analyses (PLA) test for the QIAstat–Dx® Respiratory SARS CoV–2 Panel, an automated multiplex PCR assay run on nasopharyngeal specimens to detect common viral and bacterial respiratory pathogens including SARS–CoV–2. As a PLA code, 0223U uniquely identifies a single manufacturer's test, which supports lab-level tracking, reimbursement specificity, and clinical use monitoring nationwide. National relevance stems from continued demand for multiplex respiratory diagnostics during seasonal respiratory illness and ongoing SARS–CoV–2 surveillance.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of coverage and coding context for those payers, benchmarking guidance where available, and the clinical and billing context necessary to understand how this PLA code fits into molecular diagnostic workflows. The publication outlines the service type, typical site of service, and payer coverage landscape; identifies common modifiers and coding mechanics; and highlights implications for laboratory billing, claims submission, and payer adjudication. Data not available in the input is noted where applicable.